Sunovion (United Kingdom)
On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Sunovion (United Kingdom), United Kingdom, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
42%
Total
Publications
202
Total Open
Publications
84
Total
Citations
4.9K
Open Access
Percentage
42%
Total
Publications
202
Total Open
Publications
84
Total
Citations
4.9K
Breakdown
Publisher Open
25%
Both
16%
Other Platform Open
3%
Closed
56%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 23%
20
Hybrid 23%
20
No Guarantees 54%
47
Other Platform Open
Domain 69%
29
Other Internet 33%
14
Institution 17%
7
Preprint 2%
1
Public 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 26 |
DOI | Other Internet | 14 |
Europe PMC | Domain | 4 |
European Organization for Nuclear Research | Institution | 2 |
University of Melbourne | Institution | 1 |
University of Edinburgh | Institution | 1 |
University College of Arts Crafts and Design | Institution | 1 |
Royal Netherlands Academy of Arts and Sciences | Institution | 1 |
Research Square | Preprint | 1 |
Queen Mary University of London | Institution | 1 |